BACKGROUND: P300 amplitude reduction is a consistent finding in schizophrenic patients, but it is unclear if this abnormality predates neuroleptic treatment or is present at onset of illness. METHODS: Auditory event-related potentials (ERPs), during a standard oddball paradigm, were recorded from 45 neuroleptic-naive schizophrenics, 56 drug-free, previously treated schizophrenics, and 73 healthy normal controls. Forty-seven of the schizophrenic subjects had their first episode within the past year. RESULTS: N200 amplitude did not differ among groups. P300 amplitude was significantly smaller in both neuroleptic-naive and previously treated schizophrenic groups compared to the control groups. There were no significant differences between the two schizophrenic groups in P300 amplitude. N200 and P300 latency were prolonged in previously treated schizophrenics compared to neuroleptic-naive schizophrenics and normal controls. CONCLUSIONS: The present study suggests that ERP abnormalities, especially P300 amplitude reduction, are already present prior to the administration of neuroleptic medication in the earliest stage of schizophrenia.
BACKGROUND:P300 amplitude reduction is a consistent finding in schizophrenicpatients, but it is unclear if this abnormality predates neuroleptic treatment or is present at onset of illness. METHODS: Auditory event-related potentials (ERPs), during a standard oddball paradigm, were recorded from 45 neuroleptic-naive schizophrenics, 56 drug-free, previously treated schizophrenics, and 73 healthy normal controls. Forty-seven of the schizophrenic subjects had their first episode within the past year. RESULTS: N200 amplitude did not differ among groups. P300 amplitude was significantly smaller in both neuroleptic-naive and previously treated schizophrenic groups compared to the control groups. There were no significant differences between the two schizophrenic groups in P300 amplitude. N200 and P300 latency were prolonged in previously treated schizophrenics compared to neuroleptic-naive schizophrenics and normal controls. CONCLUSIONS: The present study suggests that ERP abnormalities, especially P300 amplitude reduction, are already present prior to the administration of neuroleptic medication in the earliest stage of schizophrenia.
Authors: Nicole Pesa; Daniel F Hermens; Robert A Battisti; Manreena Kaur; Ian B Hickie; Nadia Solowij Journal: Psychopharmacology (Berl) Date: 2012-03-09 Impact factor: 4.530
Authors: Jürgen Kayser; Craig E Tenke; Christopher J Kroppmann; Daniel M Alschuler; Shiva Fekri; Shelly Ben-David; Cheryl M Corcoran; Gerard E Bruder Journal: Int J Psychophysiol Date: 2013-12-13 Impact factor: 2.997
Authors: B F O'Donnell; R W McCarley; G F Potts; D F Salisbury; P G Nestor; Y Hirayasu; M A Niznikiewicz; J Barnard; Z J Shen; D M Weinstein; F L Bookstein; M E Shenton Journal: Psychophysiology Date: 1999-05 Impact factor: 4.016
Authors: Holly K Hamilton; Veronica B Perez; Judith M Ford; Brian J Roach; Judith Jaeger; Daniel H Mathalon Journal: Schizophr Bull Date: 2018-04-06 Impact factor: 9.306
Authors: Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós Journal: Nat Rev Drug Discov Date: 2008-01 Impact factor: 84.694
Authors: Lauren E Ethridge; Jordan P Hamm; John R Shapiro; Ann T Summerfelt; Sarah K Keedy; Michael C Stevens; Godfrey Pearlson; Carol A Tamminga; Nash N Boutros; John A Sweeney; Matcheri S Keshavan; Gunvant Thaker; Brett A Clementz Journal: Biol Psychiatry Date: 2012-05-08 Impact factor: 13.382